Inclusion Criteria:

   - Patients who have undergone a radical prostatectomy (should have unmeasurable PSA) or
   radiation therapy for prostate cancer and who have high risk disease as defined by one
   of the following:

      - Node positive disease post-operatively

      - Capsule involvement

      - Seminal Vesicles involvement

      - Gleason score ≥ 8

      - >50% of core biopsies that are positive

      - Clinical Stage T2c and T3

      - Pre-op PSA > 15 plus Gleason score of 7

         - Age greater than 18

         - ECOG Performance Status 0-1

         - Serum creatinine <= 1.5 mg/dl

         - Granulocyte count >= 1500/m3, Hemoglobin > 8.0 g/dl, and platelet count >=
         100,000/m3

         - Total bilirubin <= ULN

         - AST, ALT and Alkaline Phosphatase must be within the range allowing for
         eligibility.

         - Signed patient informed consent.

         - Men of childbearing potential must be willing to consent to using effective
         contraception while on treatment and for three months thereafter.

Exclusion Criteria:

   - Peripheral neuropathy > grade 1

   - History of severe hypersensitivity to Taxotere® or other drugs formulated with
   polysorbate 80.

   - Patients who have received previous chemotherapy or are being treated on another
   clinical trial using an investigational agent.

   - Active infection within 14 days of beginning treatment

   - Patients with a serious illness or medical condition, history of significant
   neurologic or psychiatric or active infection.

   - Patients with a current malignancy. Patients with prior a history of in situ lobular
   carcinoma of the breast, basal or squamous cell skin cancer, are eligible.